These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29636047)

  • 21. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
    Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
    Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
    Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
    Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
    Gitt AK; Bramlage P; Schneider S; Tschöpe D
    Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
    Sun XF; Wang Y; Zhao WJ; Wang L; Bao DQ; Qu GR; Yao MX; Luan J; Wang YG; Yan SL
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):33-38. PubMed ID: 30605948
    [No Abstract]   [Full Text] [Related]  

  • 29. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
    Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
    Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
    De Ciuceis C; Agabiti-Rosei C; Rossini C; Caletti S; Coschignano MA; Ferrari-Toninelli G; Ragni G; Cappelli C; Cerudelli B; Airò P; Scarsi M; Tincani A; Porteri E; Rizzoni D
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):369-378. PubMed ID: 30203268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes.
    De Mattia G; Bravi MC; Laurenti O; Cassone-Faldetta M; Proietti A; De Luca O; Armiento A; Ferri C
    Diabetologia; 1998 Nov; 41(11):1392-6. PubMed ID: 9833950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
    Koska J; Lopez L; D'Souza K; Osredkar T; Deer J; Kurtz J; Salbe AD; Harman SM; Reaven PD
    Diabetes Obes Metab; 2018 Jan; 20(1):69-76. PubMed ID: 28605158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial.
    de Jager J; Kooy A; Schalkwijk C; van der Kolk J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
    J Intern Med; 2014 Jan; 275(1):59-70. PubMed ID: 23981104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of effect of a physiological elevation of plasma non-esterified fatty acid levels on insulin secretion.
    Frias JP; Basabe L; Macaraeg G; Kruszynska YT
    Diabetes Metab; 2000 Apr; 26(2):133-9. PubMed ID: 10804328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.
    Abbasi F; Carantoni M; Chen YD; Reaven GM
    Diabetes Care; 1998 Aug; 21(8):1301-5. PubMed ID: 9702437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.